AXIS 1 "RESEARCH, TECHNOLOGICAL DEVELOPMENT AND INNOVATION ACTION 1.1.4 “Support for collaborative R&D activities for the development of new sustainable technologies, products and services”
PRELIMINARY EFFICACY STUDY OF A FOOD SUPPLEMENT TO SUPPORT NCGS (Non-celiac gluten sensitivity) AND COELIAC DISEASE
Design and manufacture of a food supplement containing a plant enzyme and a probiotic. Study of the plant enzyme's proteolytic activity against gluten and the anti-inflammatory activity of the combination of active ingredients. Development of the finished product to improve its stability in terms of the viability of the probiotic strain.
Intervention realised with funding POR FESR 2014-2020 (Objective: '"Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 79.150.
PRODUCTION AND CHARACTERISATION OF AN AMARANTH EXTRACT FOR CARDIOVASCULAR HEALTH
Investigation and development of a food alternative with a health-promoting effect on the cardiovascular system. Field and vertical cultivations of different varieties of Amaranthus caudatus, production and characterisation of fluid extracts and simultaneous evaluation of biological activity.
Intervention realised with funding POR FESR 2014-2020 (Objective: "Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 35.375.
Thanks to the Regione Veneto and the European Union, Labomar has obtained important funding for the development of botanical extracts and food supplements to support health.
The precise study of products and the acquisition of new skills will enable Labomar to make important improvements in the production, proposition and positioning of its products.
Our focus is always on improving the entire production chain, services and the continuous raising of our quality standards, so that we can also address the most important international brands.
“Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.
Strategy and Goals
The Group targets the furthering of its growth and development strategy in order to consolidate and strengthen its competitive positioning.
We seek to pursue the following strategic actions:
1.
The acquisitions of recent years have allowed Labomar to become a system integrator with a presence throughout the supply chain, upstream with Labomar Next, Labiotre and PrintingPack for the sourcing of the raw material and the pack, and downstream with the companies dealing directly with the customer (Labomar, Welcare, ImportFab and LaboVar).
2.
Tapping into the synergies with Importfab, Welcare, Labiotre, LaboVar and Labomar Next so as to expand the portfolio and the commercial offer, sharing the results from research and development and integrating marketing activities. In addition, through its investees Importfab and Labomar Next, Labomar shall pursue the opportunities presented by the growing cannabis for pharmaceutical use market.
3.
Not only cross-selling, but also the international expansion of the Labomar Group, thanks to the companies joining the Group and allowing us to penetrate new geographical areas – particularly the United Arab Emirates and China. It is fundamental that processes and policies are also integrated to obtain comprehensive synergies.
4.
Focus on a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects. This focus continues to be evident across all Labomar projects. The company some time ago launched the process to obtain B-Corp Certification.
5.
Continuous strengthening of the Research and Development division through investments in projects focused on creating new formulations and obtaining new patents, in addition to the establishment of strategic collaborations with Universities, clinics and research laboratories in the fields of pharmacology and pharmaceutical technology.
6.
Strengthening its position in the cosmetics segment, both leveraging the knowledge and expertise at Labomar, and through ImportFab.
7.
Focus on investments to expand and restructure production to ensure efficiencies, according to Lean Transformation principles.
We use technical and profiling cookies to make sure you can have the best experience on our site.